Advertisement
| double beta lactam therapy: Antimicrobial Therapy in Veterinary Medicine Steeve Giguère, John F. Prescott, Patricia Dowling, 2013-07-25 The Fifth Edition of Antimicrobial Therapy in Veterinary Medicine, the most comprehensive reference available on veterinary antimicrobial drug use, has been thoroughly revised and updated to reflect the rapid advancements in the field of antimicrobial therapy. Encompassing all aspects of antimicrobial drug use in animals, the book provides detailed coverage of virtually all types of antimicrobials relevant to animal health. Now with a new chapter on antimicrobial therapy in zoo animals, Antimicrobial Therapy in Veterinary Medicine offers a wealth of invaluable information for appropriately prescribing antimicrobial therapies and shaping public policy. Divided into four sections covering general principles of antimicrobial therapy, classes of antimicrobial agents, special considerations, and antimicrobial drug use in multiple animal species, the text is enhanced by tables, diagrams, and photos. Antimicrobial Therapy in Veterinary Medicine is an essential resource for anyone concerned with the appropriate use of antimicrobial drugs, including veterinary practitioners, students, public health veterinarians, and industry and research scientists. |
| double beta lactam therapy: Recent Advances in the Chemistry of [beta]-lactam Antibiotics P. H. Bentley, R. Southgate, 1989 |
| double beta lactam therapy: Severe Community Acquired Pneumonia Jordi Rello, Kenneth V. Leeper, Kenneth Leeper, 2001-06-30 Severe Community Acquired Pneumonia is a book in which chapters are authored and the same topics discussed by North American and European experts. This approach provides a unique opportunity to view the different perspectives and points of view on this subject. Severe CAP is a common clinical problem encountered in the ICU setting. This book reviews topics concerning the pathogenesis, diagnosis and management of SCAP. The discussions on the role of alcohol in severe CAP and adjunctive therapies are important topics that further our understanding of this severe respiratory infection. |
| double beta lactam therapy: Penicillins and Cephalosporins Robert B. Morin, Marvin Gorman, 2014-05-10 Chemistry and Biology of ?-Lactam Antibiotics, Volume 1: Penicillins and Cephalosporins provides information pertinent to the study of antibiotics containing the ?-lactam moiety. This book discusses the occurrence of a group of ?-lactam antibiotics structurally related to cephalosporin C. Organized into five chapters, this volume begins with an overview of the mechanism of action of ?-lactam antibiotics that caused many microbiologists to develop screening tools for the detection of the ?-lactam moiety. This text then discusses the discovery of the nocardicins, the thienamycins, and olivanic acids. Other chapters provide a summary of the essential penicillin sulfoxide chemistry that gave rise to many compounds. This book discusses as well the ability of chemists to predict the level of biological activity of a compound from knowledge of its structure through theoretical and physicochemical studies. The final chapter deals with quantitative structure–activity relationships. This book is a valuable resource for microbiologists, chemists, and scientists. |
| double beta lactam therapy: Transplant Infections Raleigh A. Bowden, Per Ljungman, David R. Snydman, 2010 Transplant Infections is a practical, clinically focused reference covering the common and more unusual bacterial, viral, and fungal infections affecting patients who have received stem cell or solid organ transplants. It provides a comprehensive review of the epidemiology, diagnosis, and management of opportunistic infections and presents strategies for infection prevention and control. Highlights of the Third Edition include a chapter on new immunosuppressive agents and expanded coverage of tropical infections and West Nile virus. |
| double beta lactam therapy: Drug-Induced Liver Injury , 2019-07-13 Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series |
| double beta lactam therapy: Clinical Nephrotoxins Marc E. de Broe, George A. Porter, William M. Bennett, G.A. Verpooten, 2007-05-08 To you the reader, the joy of discovery begins, for We continue in our goal of providing a text which us the job is done. In this edition, we have corrected is useful, not only to the clinician, but of equal interest past deficiencies, added new topics, expanded infor- to the investigator. The selection of content has been mation regarding the pediatric age group, provided directed at topics of current interest rather than those up to date (March 2003) references, while remaining of historic contribution. We have stressed the cont- true to our concept of a multi-national author book. bution of cell biology and pathophysiology, were it We continue to believe that scientific information is an exists, believing it provides both a better understa- international commodity whose interpretation and ap- ing of toxic injury when known, and a rational dir- plication are strongly influenced by both the cultural tion for therapy and prevention. and ethnic background of the observer. The oppor- nity to share in the rich diversity of the international We are encouraged by the accumulation of rec- scientific community remains a fundamental goal of nized risk factors, which allow pre-treatment strati- this endeavor. To participate as equals leads to mu- cation of our patients’ relative risk and allow us to - tual respect and peer appreciation. The sharing of in- cus our preventative techniques on the individuals tellectual resources fostered by this effort should and most likely to gain the greatest benefit. |
| double beta lactam therapy: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases John E. Bennett, MD, MACP, Raphael Dolin, MD, Martin J. Blaser, MD, 2014-08-28 After thirty five years, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. John E. Bennett and Raphael Dolin along with new editorial team member Dr. Martin Blaser have meticulously updated this latest edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition helps you identify and treat whatever infectious disease you see. Get the answers to questions you have with more in-depth coverage of epidemiology, etiology, pathology, microbiology, immunology, and treatment of infectious agents than you'll find in any other infectious disease resource. Find the latest diagnoses and treatments for currently recognized and newly emerging infectious diseases, such as those caused by avian and swine influenza viruses. Put the latest knowledge to work in your practice with new or completely revised chapters on influenza (new pandemic strains); new Middle East respiratory syndrome (MERS) virus; probiotics; antibiotics for resistant bacteria; antifungal drugs; new antivirals for hepatitis B and C; Clostridium difficile treatment; sepsis; advances in HIV prevention and treatment; viral gastroenteritis; Lyme disease; Helicobacter pylori; malaria; infections in immunocompromised hosts; immunization (new vaccines and new recommendations); and microbiome. Benefit from fresh perspectives and global insights from an expanded team of international contributors. Find and grasp the information you need easily and rapidly with newly added chapter summaries. These bulleted templates include diagnosis, therapy, and prevention and are designed as a quick summary of the chapter and to enhance relevancy in search and retrieval on Expert Consult. Stay current on Expert Consult with a thorough and regularly scheduled update program that ensures access to new developments in the field, advances in therapy, and timely information. Access the information you need easily and rapidly with new succinct chapter summaries that include diagnosis, therapy, and prevention. Experience clinical scenarios with vivid clarity through a richly illustrated, full-color format that includes 1500 photographs for enhanced visual guidance. |
| double beta lactam therapy: The Pharmacist's Guide to Antimicrobial Therapy and Stewardship Sarah M. Wieczorkiewicz, Carrie Sincak, 2015-12-15 When a patient comes in with a suspected infectious disease, knowledge is power. Now this knowledge is simplified, comprehensive and easy to find. The Pharmacist's Guide to Antimicrobial Therapy and Stewardship puts all the necessary information in one place, including: Evaluating potentially infected patients Identifying the infection's suspected source and related organisms Comparing the range of anti-infectives Knowing the factors that impact treatment Developing an antimicrobial stewardship program A step-wise approach walks logically from overall key concepts to disease- and drug-specific information. Disease states are summarized for easy reference. Tables make it easy to evaluate recommended treatment options. In infectious disease management, when answers are seldom black and white, this guide helps pharmacists make confident decisions. |
| double beta lactam therapy: Annual Update in Intensive Care and Emergency Medicine 2011 Jean-Louis Vincent, 2011-04-02 The Annual Update compiles the most recent developments in experimental and clinical research and practice in one comprehensive reference book. The chapters are written by well recognized experts in the field of intensive care and emergency medicine. It is addressed to everyone involved in internal medicine, anesthesia, surgery, pediatrics, intensive care and emergency medicine. |
| double beta lactam therapy: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| double beta lactam therapy: Antimicrobial Resistance Maria Cristina Ossiprandi, 2015-11-26 Antibiotic resistance has become a worldwide health issue, globally recognized as the first priority by WHO. Many forms of resistance can spread with remarkable speed and cross international boundaries. World health leaders are devoting efforts to the problem by planning strategies for monitoring the effectiveness of public health interventions and detecting new trends and threats. This volume focuses on the problem from different perspectives, taking into consideration geographical dissemination (soil and water), human medicine (methicillin-resistant Staphylococcus aureus and Klebsiella pneumoniae) and veterinary (Enterococcus spp.) impact and molecular analysis. The purpose of this volume is to provide a useful tool for control and prevention and to discuss useful epidemiological data concerning ways of obtaining an accurate picture of resistance in different communities. |
| double beta lactam therapy: Antimicrobial Therapy I , 1995 |
| double beta lactam therapy: Abdominal Sepsis Massimo Sartelli, Matteo Bassetti, Ignacio Martin-Loeches, 2018-03-20 This book examines in detail the topic of sepsis, with a focus on intra-abdominal sepsis. Particular attention is devoted to source control in the management of the infection, antimicrobial therapy and sepsis support, which represent the cornerstones of treating patients with this problem. The importance of a multidisciplinary approach is highlighted not only by the instructive and informative sections on the acute manifestations of appendicitis, cholecystitis, and cholangitis, perforations and diverticulitis, Clostridium difficile infection and the role of candida in abdominal sepsis, but also by an extensive discussion of issues including antimicrobial resistance, damage control surgery, principles of antimicrobial therapy, hemodynamic support, adjunctive therapies, and thromboprophylaxis. Abdominal sepsis is the host’s systemic inflammatory response to intra-abdominal infections. It is associated with significant morbidity and mortality rates, and represents the second most common cause of sepsis-related mortality at intensive care units. Gathering contributions by authoritative experts from all around the world, this book will allow acute care surgeons, abdominal surgeons, intensive care clinicians, and students to broaden their understanding of intra-abdominal sepsis in daily clinical practice. |
| double beta lactam therapy: Manual of Childhood Infections Mike Sharland, Andrew Cant, E. Graham Davies, David A. C. Elliman, Susanna Esposito, Delane Shingadia, Adam Finn, 2011-04-07 This manual gives information on the causative organisms, epidemiology and clinical features of all important childhood infections. It includes guidance on the clinical management of the infections and on steps to be taken to prevent future cases. |
| double beta lactam therapy: Core Topics in Cardiothoracic Critical Care Kamen Valchanov, Nicola Jones, Charles W. Hogue, 2018-07-05 Most patients with critical cardiac or thoracic conditions will at some stage pass through the cardiothoracic critical care unit. Critical care presents more complex clinical data than any other area of medicine. The new edition of Core Topics in Cardiothoracic Critical Care focuses on the latest practise in the management of patients in cardiothoracic intensive care. The practice of cardiothoracic critical care medicine is constantly evolving, and this new edition reflects the modernized learning styles for trainees. Each chapter includes key learning points as well as sample multiple choice questions and answers to assist in exam preparation. This edition also features updated chapters on ECMO, perioperative management of patients undergoing emergency cardiothoracic surgery, and advanced modes of organ support for patients. This text provides key knowledge in a concise and accessible manner for trainees, clinicians and consultants from specialities and disciplines such as cardiology and anaesthesia, and nursing and physiotherapy. |
| double beta lactam therapy: Medical Pharmacology and Therapeutics E-Book Derek G. Waller, Tony Sampson, 2013-08-07 This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice. Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examples Includes more on genetic issues Drug tables made more concise to make information more accessible Fully updated to reflect current clinical practice |
| double beta lactam therapy: Small Animal Clinical Pharmacology and Therapeutics Dawn Merton Boothe, 2011-04-05 Confidently utilize the rapidly growing selection of pharmaceuticals used to treat small animals. Small Animal Pharmacology and Therapeutics, 2nd Edition helps you understand both the therapeutic uses of common pharmaceuticals and the pharmacology behind them, giving you all of the information you need to design and modify dosing regimens, identify factors that cause drugs to fail, and anticipate adverse drug reactions. Comprehensive approach emphasizes the use of drugs for prevention as well as treatment. Clear, consistent organization makes it easy to find the information you need when you need it. Dosage tables help you find essential pharmaceutical information at a glance. Pharmacogenetics chapter helps you understand how to use this emerging science to find the right dose for each patient, optimizing efficiency and minimizing toxicity. Routes of administration and sample pharmaceutical calculations provide fast, efficient access to comprehensive drug administration all in one inclusive resource. Multiple chapters on Antimicrobial Drugs and Antimicrobial Therapy highlight the impact of antimicrobial resistance on current practice. |
| double beta lactam therapy: Managing Infections in Patients With Hematological Malignancies Michael Kleinberg, 2009-10-20 Managing infections that complicate care of neutropenic patients with leukemia and hematopoietic stem cell recipients has become a distinct specialty. In Managing Infections in Patients with Hematological Malignancies, the authors and editor draw on their extensive expertise while providing a roadmap for hematologists to efficiently manage the complex infections within their patients. The first section of the text reviews viral, bacterial, and fungal pathogens, and provides brief descriptions of the microbes and diseases they cause in patients with hematological malignancies. The second section is devoted to management of infections in patients with the different underlying hematological malignancies, while the third addresses several important topics that are often ignored in most books about infections and hematological malignancies. Managing Infections in Hematological Malignancies is a useful tool for all clinicians and practicing hematologists who treat individual patients and aspire to build stronger infectious diseases programs within their respective cancer centers. |
| double beta lactam therapy: Clinical Approach to Infection in the Compromised Host Robert H. Rubin, Lowell S. Young, 2013-11-11 `With admirable clarity the authors-all highly regarded experts in their respective fields-present the clinician with a supremely readable and practical text. The emphasis here is pragmatic, although there is sufficient pathogenesis and physiology to provide a fine balance.'-Journal of the American Medical Association, from a review of the second edition. This updated and profusely illustrated edition is 75% larger than its first incarnation. New coverage includes transplantation medicine, AIDS, patient management, and host-parasite interactions. |
| double beta lactam therapy: na , 2012-02-13 |
| double beta lactam therapy: Anesthetic Pharmacology Alex S. Evers, Mervyn Maze, Evan D. Kharasch, 2011-03-10 In recent years our understanding of molecular mechanisms of drug action and interindividual variability in drug response has grown enormously. Meanwhile, the practice of anesthesiology has expanded to the preoperative environment and numerous locations outside the OR. Anesthetic Pharmacology: Basic Principles and Clinical Practice, 2nd edition, is an outstanding therapeutic resource in anesthesia and critical care: Section 1 introduces the principles of drug action, Section 2 presents the molecular, cellular and integrated physiology of the target organ/functional system and Section 3 reviews the pharmacology and toxicology of anesthetic drugs. The new Section 4, Therapeutics of Clinical Practice, provides integrated and comparative pharmacology and the practical application of drugs in daily clinical practice. Edited by three highly acclaimed academic anesthetic pharmacologists, with contributions from an international team of experts, and illustrated in full colour, this is a sophisticated, user-friendly resource for all practitioners providing care in the perioperative period. |
| double beta lactam therapy: Clinical Approach to Infection in the Compromised Host R. Rubin, 2013-11-11 Infection in the Compromised Host has become a classic chapter in textbooks devoted to infectious diseases and internal medicine. The numbers of compromised hosts are increasing in the era of modem medicine because of our expanded capabilities to deal with difficult diseases, especially neoplasms. As a consequence, microbiologic complications related to the intensive care administered to these patients are increasing as well. Under these circum stances, not only does the underlying illness create conditions favorable for the development of unusual infections, but often the therapy contributes to the acquisition of potential pathogens that turn into agents responsible for severe and frequently fatal disease. Granulocytopenia and immunosuppression have been the two key fac tors in predisposing patients with cancer and other serious diseases to severe bacterial infections. Colonization by hospital-acquired pathogens and breaks in the anatomic barriers-as a result of disease or medical intervention-have contributed to the high incidence of infectious diseases in these patients. Although there is some overlap between the types of infection in granulocytopenic and immunosuppressed hosts, each ofthese clinical entities has distinctive features thatjustify considering them separately, reserving the term immunocompromised hosts only when refer ring to patients who are predisposed to opportunistic infections. For about two decades, infections in granulocytopenic patients have attracted the atten tion of clinicians because they represent a model for the study of antimicrobial drugs in hosts deprived of an essential element of defense against bacterial infection, that is, an adequate number of normally functioning granulocytes. |
| double beta lactam therapy: Braunwald's Heart Disease E-Book Douglas P. Zipes, Peter Libby, Robert O. Bonow, Douglas L. Mann, Gordon F. Tomaselli, 2018-01-09 Trusted by generations of cardiologists for the latest, most reliable guidance in the field, Braunwald’s Heart Disease, 11th Edition, remains your #1 source of information on rapidly changing clinical science, clinical and translational research, and evidence-based medicine. This award-winning text has been completely updated, providing a superior multimedia reference for every aspect of this fast-changing field, including new material about almost every topic in cardiology. |
| double beta lactam therapy: Antimicrobial Resistance Robert C. Owens, Ebbing Lautenbach, 2007-12-22 This publication provides a state-of-the-art overview of key issues related to antimicrobial resistance, including a focus on key pathogens causing common healthcare-associated and community-acquired infections. The epidemiology and therapeutic considerations of these antimicrobial resistant organisms are discussed, as well as the clinical and heal |
| double beta lactam therapy: Koda-Kimble and Young's Applied Therapeutics Brian K. Alldredge, Robin L. Corelli, Michael E. Ernst, 2012-02-01 Rev. ed. of: Applied therapeutics: the clinical use of drugs / edited by Mary Anne Koda-Kimble ... [et al.]. 9th ed. c2009. |
| double beta lactam therapy: Management of Infectious Complication in Cancer Patients Gary A. Noskin, 2007-11-23 Infection is a major cause of morbidity and mortality in patients with neoplastic disease because of compromised host defenses. These defects result in an increased risk of infection and its complications. The nature of the underlying malignancy, the immunodeficiencies associated with it, and the treatments directed against it are all important determinants of infection. In recent years, the introduction of more intensive chemotherapeutic regimes and the widespread use of bone marrow and peripheral stem cell transplantation have changed the pattern of infection in many patients. Furthermore, the increasing use of central venous access devices and antimicrobial prophylaxis has changed the epidemiology of infection in these patients as well. The goal of this volume in the Cancer Treatment and Research series is to emphasize that while the management of infection in cancer patients is common, it is constantly changing. With the increasing complexity of these patients, optimal management requires a multidisciplinary approach. Ultimately, it is hoped that this book will assist clinicians in the diagnosis, management, and prevention of infection in order to optimize care for patients with cancer. |
| double beta lactam therapy: Drug Interactions in Infectious Diseases Stephen C. Piscitelli, Keith A. Rodvold, Manjunath P. Pai, 2011-09-08 The revised and up-to-date third edition of Drug Interactions in Infectious Diseases delivers a text that will enhance your clinical knowledge of the complex mechanisms, risks, and consequences of drug interactions associated with antimicrobials, infection, and inflammation. The third edition features five new chapters that cover material not addressed in previous editions. These new chapters describe interactions with a number of drug classes such as non-HIV antiviral, antimalarial, antiparasitic, antihelmintic, macrolide, azalide and ketolide agents. A novel chapter on probe cocktail studies has been included to highlight an important research tool for drug development. These chapters address material that cannot be retrieved easily in the medical literature. The highly acclaimed food-drug interactions as well as the study design and analysis chapters remain definitive references. The newly written drug-cytokine interaction highlights the need for our improved understanding of the complex interrelationship of acute infection, inflammation, and the risk of drug interactions. Informative tables on specific drug-drug interactions are provided throughout the chapters as a quick clinical resource. The Third Edition of Drug Interactions in Infectious Diseases is a distillation of relevant drug interactions associated with antimicrobials, infection, and inflammation. This concise review of the mechanisms and strategies to manage drug interactions should be valuable to all health care practitioners. Features • Definitive reference source of up-to-date information on antimicrobial drug interactions • Informative tables on the degree of interaction for specific antimicrobial agents • In-depth discussion of mechanisms and potential mechanistic pathways of interaction • New chapters on non-HIV antiviral, antimalarial, antiparasitic, and macrolide, azalide and ketolide agents • New chapter on probe-cocktail studies as a research tool to study drug-drug interactions • Inclusion of new antimicrobial agents and their associated drug interactions • First rate chapters on study design and analysis, and drug-food interactions • A fresh perspective on drug-cytokine interactions • Authoritative chapter on regulatory considerations of drug interactions during drug development |
| double beta lactam therapy: Infectious Complications in Bone Marrow Transplantation Stephen C. Schimpff, Jean Klastersky, 2012-12-06 As the demographics of the population shift toward an increasingly aged society, the number of individuals with cancer increases and with it the need to give the most comprehensive possible health care delivery. Although much has been written about the specific therapy best suited for the various types of cancer and about the basic and clinical research which has dramatically improved treat ment, overall patient care requires attention to supportive care, which includes such items as pain management, the use of blood products, nutrition, and psychosocial needs. Yet infection remains the leading cause of death in cancer patients and is a major cause of morbidity and hospitaliza tion, making it a major aspect of the supportive care of cancer patients. It therefore deserves a full exposition. Bone marrow transplantation is increasingly being utilized as part of a therapeutic modality in the treatment of cancer patients. Transplantation patients are at such a particularly high risk of developing a wide variety of different types of infection, that they inevitably can serve as an excellent framework for discussion of all the types of infections that occur during the treatment of cancer. The patient undergoing allogeneic bone marrow transplantation is at particularly high risk of infection due to the major perturbations of host defenses, which include granulo cytopenia, cellular immune dysfunction, humoral immune dysfunction, blood product transfusions, and vascular access devices. Each of these perturbations results in a different set of infectious disease problems. |
| double beta lactam therapy: Infectious Diseases in Critical Care Jordi Rello, 2007-03-20 Critical care practitioners are often the initial providers of care to seriously ill patients with infections. This book provides clinicians practicing in the intensive care unit with a reference to help guide their care of infected patients. It brings together a group of international authors to address important topics related to infectious diseases for the critical care practitioner. |
| double beta lactam therapy: Practical Cardiology Ragavendra R. Baliga, Kim A. Eagle, 2020-08-10 This thoroughly updated new edition of the classic practical textbook provides a user-friendly, authoritative guide to evaluation of common cardiovascular symptoms and evaluation and management of common cardiovascular conditions. Coverage also includes clinical challenges such as management of chronic anticoagulation, assessing and minimizing cardiac risk in noncardiac surgery, and management of the cardiac surgery patient. Numerous tables and algorithms help readers find information quickly and aid in clinical decision-making. Practical Cardiology, Evaluation and Treatment of Common Cardiovascular Disorders reflects the current American College of Cardiology/American Heart Association guidelines and provides a concise yet comprehensive handbook presents practical information on the common cardiovascular problems that clinicians encounter daily. |
| double beta lactam therapy: Braunwald's Heart Disease - E-Book Peter Libby, 2021-10-15 Current, comprehensive, and evidence-based Braunwald's Heart Disease remains the most trusted reference in the field and the leading source of reliable cardiology information for practitioners and trainees worldwide. The fully updated 12th Edition continues the tradition of excellence with dependable, state-of-the-art coverage of new drugs, new guidelines, more powerful imaging modalities, and recent developments in precision medicine that continue to change and advance the practice of cardiovascular medicine. Written and edited by global experts in the field, this award-winning text is an unparalleled multimedia reference for every aspect of this complex and fast-changing area. - Offers balanced, dependable content on rapidly changing clinical science, clinical and translational research, and evidence-based medicine. - Includes 76 new contributing authors and 14 new chapters that cover Artificial intelligence in Cardiovascular Medicine; Wearables; Influenza, Pandemics, COVID-19, and Cardiovascular Disease; Tobacco and Nicotine Products in Cardiovascular Disease; Cardiac Amyloidosis; Impact of the Environment on Cardiovascular Health, and more. - Features a new introductory chapter Cardiovascular Disease: Past, Present, and Future by Eugene Braunwald, MD, offering his unique, visionary approach to the field of cardiology. Dr. Braunwald also curates the extensive, bimonthly online updates that include Hot Off the Press (with links to Practice Update) and Late-Breaking Clinical Trials. - Provides cutting-edge coverage of key topics such as proteomics and metabolomics, TAVR, diabetocardiology, and cardio-oncology. - Contains 1,850 high-quality illustrations, radiographic images, algorithms, and charts, and provides access to 215 videos called out with icons in the print version. - Highlights the latest AHA, ACC, and ESC guidelines to clearly summarize diagnostic criteria and clinical implications. - Provides tightly edited, focused content for quick, dependable reference. Flexible format options include either one or two volumes in print, as well as a searchable eBook with ongoing updates. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. |
| double beta lactam therapy: Cancer and the Heart Michael S. Ewer, 2019-11-20 In Cancer and the Heart, third edition, Dr. Ewer and colleagues at MD Anderson are joined by national and international authorities who contributed to the 28 chapters of this volume. The various authors present their insights into the effects of anticancer drugs and radiation treatment on the heart, and other organ systems. Discussions are advanced on imaging strategies and techniques with an emphasis on specific clinical problems experienced by physicians and their patients. Readers will find a useful reference intended to help them recognize the decision-making dilemmas they face providing optimal tumor management, and a useful resource to help them and their cancer patients cope with inevitable challenges. |
| double beta lactam therapy: Antibiotic and Chemotherapy E-Book Roger G. Finch, David Greenwood, Richard J. Whitley, S. Ragnar Norrby, 2010-11-30 Well-respected and widely regarded as the most comprehensive text in the field, Antibiotic and Chemotherapy, 9th Edition by Drs. Finch, Greenwood, Whitley, and Norrby, provides globally relevant coverage of all types of antimicrobial agents used in human medicine, including all antiviral, antiprotozoan and anthelminthic agents. Comprehensively updated to include new FDA and EMEA regulations, this edition keeps you current with brand-new information about antiretroviral agents and HIV, superficial and mucocutaneous myscoses and systemic infections, management of the immunocompromised patient, treatment of antimicrobial resistance, plus coverage of new anti-sepsis agents and host/microbe modulators. Reference is easy thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Offer the best possible care and information to your patients about the increasing problem of multi-drug resistance and the wide range of new antiviral therapies now available for the treatment of HIV and other viral infections. Stay current with 21 new chapters including the latest information on superficial and mucocutaneous mycoses, systemic infections, anti-retroviral agents, and HIV. Get fresh perspectives and insights thanks to 21 newly-authored and extensively re-written chapters. Easily access information thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Apply the latest treatments for anti-microbial organisms such as MRSA, and multi-drug resistant forms of TB, malaria and gonorrhea. Keep up on the latest FDA and EMEA regulations. |
| double beta lactam therapy: Irwin and Rippe's Intensive Care Medicine Richard S. Irwin, 2017-12-18 With a focus on evidence-based, state-of-the-art information throughout, the eighth edition of Irwin and Rippe’s Intensive Care Medicine offers authoritative guidance to the wide variety of specialty physicians and non-physicians practicing in the adult intensive care environment. This comprehensive textbook covers both the theoretical and practical aspects of the field, and has been completely updated to provide encyclopedic, interprofessional coverage to support practitioners in every area of this complex field. |
| double beta lactam therapy: Cumulated Index Medicus , 1996 |
| double beta lactam therapy: Infectious Diseases in Critical Care Medicine Burke A. Cunha, 1998-05-27 This invaluable clinical guide offers the only reference on infectious diseases encountered in intensive care patients-discussing infectious disease problems in the critical care unit and therapy. No other book describes in practical terms the mimics of infection and how to differentiate colonization from infection! Written by internationally renowned experts, Infectious Diseases in Critical Care Medicine differentiates between sepsis and conditions that can imitate sepsis highlights key diagnostic findings in all major infectious disease problems in critical care includes practical infection control measures provides easy to use recommendations on empiric antibiotic therapy furnishes a simple, effective method of adjusting drug doses in patients with abnormal hepatic and kidney function presents strategies for controlling resistance in critical care With over 2500 bibliographic citations and more than 200 tables, drawings, photographs, micrographs, and x-rays, Infectious Diseases in Critical Care Medicine is an indispensable resource for infectious disease specialists; intensive and critical care physicians; pulmonologists; primary care physicians; internists; hospitalists; medical house officers; and pulmonary, critical care, and infectious disease fellows. |
| double beta lactam therapy: Hot Topics in Lung Infections, An Issue of Infectious Disease Clinics of North America Rachael Lee, Helen W. Boucher, 2024-03-28 In this issue of Infectious Disease Clinics, guest editors Rachael Lee and Helen W. Boucher bring their considerable expertise to the topic of Lung Infections. Top experts in the field provide important updates on hot topics such as Viral Pneumonias, Infectious Pulmonary Diseases,Infections in Heart and Lung Transplant Recipients, and more. - Contains 12 practice-oriented topics including Opportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial; Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis; Coronavirus Disease-2019 in the Immunocompromised Host; Novel and Rapid Diagnostics for Common Infections in the Critically Ill Patient; and more. - Provides in-depth clinical reviews on lung infections, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| double beta lactam therapy: Clinical Infectious Disease David Schlossberg, 2015-04-23 A fully updated version of this popular, clinically oriented, user-friendly text on infectious disease, with even more helpful graphics, tables, algorithms and images. It is packed full of information on diagnosis, differential diagnosis and therapy. In addition to the traditional organization of organ-system and pathogen-related information, this text also includes clinically helpful sections on the susceptible host (with individual chapters, for example, on the diabetic, the elderly, the injection drug user and the neonate), infections related to travel, infections related to surgery and trauma, nosocomial infection and bioterrorism. Positioned between the available encyclopedic tomes and the smaller pocket guides, this is a convenient, comprehensive and highly practical reference for all those practising in infectious diseases as well as internal or general medicine. |
| double beta lactam therapy: The AHA Guidelines and Scientific Statements Handbook Valentin Fuster, 2011-09-23 Society-sanctioned guidelines on care are valuable tools, but accessing key information from the often complicated statements has been a daunting task. Now, practitioners and their institutions have a clear path to successful application of guidelines from the American Heart Association. This book outlines the key AHA guidelines, Statements, and Performance Measures and includes comparisons with the associated European guidelines. This book also has a strong online component, which will alert users who sign up to new updates to the guidelines and other relevant information. It will also have links through to the full guidelines and statements. |
What is the difference between float and double? - Stack Overflow
Dec 31, 2021 · Type double, 64 bits long, has a bigger range (*10^+/-308) and 15 digits precision. Type long double is nominally 80 bits, though a given compiler/OS pairing may store it as 12 …
How do I print a double value with full precision using cout?
Dec 17, 2020 · A double is a floating point type, not fixed point. Do not use std::fixed as that fails to print small double as anything but 0.000...000. For large double, it prints many digits, …
Difference between long double and double in C and C++
Apr 22, 2015 · The standard only requires that long double is at least as precise as double, so some compilers will simply treat long double as if it is the same as double. But, on most x86 …
Correct format specifier for double in printf - Stack Overflow
Format %lf is a perfectly correct printf format for double, exactly as you used it. There's nothing wrong with your code. There's nothing wrong with your code. Format %lf in printf was not …
Reading in double values with scanf in c - Stack Overflow
Oct 7, 2017 · I found out that there is a problem with the length of double on 32 bit OS, so that you are forced to use scanf("%lf", &f) to read in a double. No matter what I do, second value is …
decimal vs double! - Which one should I use and when?
Jul 22, 2009 · To clear this up double does not have 16 digits - that is only the number of meaningful digits. Floats are based around exponents in base 2 math - some base 10 …
How to Code Double Quotes via HTML Codes - Stack Overflow
Feb 28, 2013 · I was just curious as to why there needs to be 3 different ways to code a double quotes in html codes, for example. – H. Ferrence Commented Feb 28, 2013 at 12:48
Difference between decimal, float and double in .NET?
Mar 6, 2009 · Double: It is also a floating binary point type variable with double precision and 64 bits size(15-17 significant figures). Double are probably the most generally used data type for …
What is the size of float and double in C and C++? [duplicate]
Aug 27, 2014 · The set of values of the type float is a subset of the set of values of the type double; the set of values of the type double is a subset of the set of values of the type long …
What does the !! (double exclamation mark) operator do in …
The double negation operator !! calculates the truth value of a value. It's actually two operators, where !!x means !(!x), and behaves as follows: If x is a false value, !x is true, and !!x is false. If …
Discontinuing β-lactam treatment after 3 days for patients …
clinical stability criteria after 3 days of treatment with β-lactam therapy were randomly assigned (1:1) to receive β-lactam therapy (oral amoxicillin 1 g plus clavulanate 125 mg three times a …
D A THERAPY AND RELATIONSHIP WITH PENICILLIN …
EVALUATION OF IN VITRO ACTIVITY OF DOUBLE BETA-LACTAM THERAPY AND RELATIONSHIP WITH PENICILLIN BINDING PROTEINS ACTIVITY IN ESCHERICHIA COLI …
Cross-Reactivity to Meropenem and Ertapenem Without …
Carbapenems have a beta-lactam ring that might prone to cause hypersensitivity reactions. We proposed that the clinical cross-reactivity between the individual carbapenems will develop …
Dual β-lactam therapy to improve treatment outcome …
Mar 23, 2024 · lacks a firm evidence base. Dual b-lactam and b-lactam/b-lactamase inhibitor combinations may be interesting leads to improve treatment outcomes. Objectives: To …
Antibiotic Protocol for Empiric Therapy of Nosocomial …
o Severe beta-lactam allergy: Vancomycin* plus aztreonam o Consider addition of the following agents based on severity of illness and likelihood of ... Broad spectrum empiric antibiotic …
Foundations in Microbiology - Bellarmine University
•Beta-lactam antimicrobials - all contain a highly reactive 3 carbon, 1 nitrogen ring •Primary mode of action is to interfere with cell wall synthesis. •Greater than ½ of all antimicrobic drugs are …
IDSA Guidelines on the Treatment of MRSA Infections in …
Empiric therapy for five to 10 days is recommended pending culture results for outpatients with purulent ... A beta-lactam antibiotic (e.g., cefazolin) may be considered in hospital-
HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST
1. Mapping the preferred affinities of commonly used beta-lactam agents to penicillin-binding proteins 2. Is synergy in double beta-lactam therapy predicted by affinities to penicillin-binding …
Comparable Efficacy and Better Safety of Double β-Lactam …
KEYWORDS double beta-lactam, Gram-negative bacteria, beta-lactamase inhibitor, combination therapy, meta-analysis, randomized controlled clinical trial A ntimicrobial resistance is causing …
Sepsis - University of California, Los Angeles
Two sets of blood cultures must be obtained prior to initiating antibiotics to help guide therapy. For proper bundle compliance, use the physician Sepsis Order set in CareConnect. ... Severe beta …
Drug Name Ceftazidime/Avibactam
Drug Class Beta lactam (Cephalosporin) with non-beta lactam beta lactamase inhibitor Restriction level ID consult required ... Answer of “no” to any of the above questions should prompt …
CONTRAINDICATIONS ORLYNVAHTM for ORLYNVAH lactam …
anaphylaxis, and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs [see Contraindications (4)]. Before therapy with ORLYNVAH is instituted, …
Controlled Trials of Double Beta-Lactam Therapy with …
Current double beta-lactam antibiotic regimens usually pair a third-generation cephalosporin with an antipseudomonal ureidopenicillin. In our initial trial of double beta-lactam antibiotic therapy, …
Double Beta Lactam Therapy Full PDF - staging …
Double Beta Lactam Therapy Offers over 60,000 free eBooks, including many classics that are in the public domain. Open Library: Provides access to over 1 million free eBooks, including …
Comparative effectiveness of β-lactam versus vancomycin …
trol was achieved more often in the β-lactam (18.3 and 25.2 % respectively) compared to the vancomycin group (9.7 and 15.3 % respectively). The prevalence of infective endocarditis was …
CASE REPORT One stage extraction and reimplantation of …
and spondiloscitis due to E. faecalis treated with double beta-lactam combination: ampicillin plus ceftobiprole Maria Lucia Narducci1, Davide Pecori2, ... nation therapy with ampicillin, based on …
Use of Aminoglycosides in lmmunocompromised Patients
receiving amikacin than in recipients of the double beta-lactam regi- men. From the Department of infectious Diseases, Uni- vereity of California School of Medicine, Center for Health Sciences, …
Comparison of Cefoperazone and Mezlocillin with Imipenem …
to the double beta-lactam combination received cefo- perazone 2 g intravenously every 12 hours and mezlo- cillin 4 g intravenously every six hours. The imi- penemkilastatin was administered …
Guidance on management of uncomplicated bloodstream …
Candidates for Short Course & Oral Therapy: Patients with Gram-negative bloodstream infection (GN-BSI) that meet all of the following criteria may ... rounded to nearest double strength (DS, …
JID 1990;162 (October) Concise Communications 983 - JSTOR
cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am J Med 1988;85:17-20 7. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin …
Guideline for the Management of Community-Acquired …
Most CAP patients should be treated with agents targeting typical respiratory pathogens (beta-lactam + macrolide). Certain CAP patients are at increased risk of MDRO infection, but …
Duration of Antibiotic Treatment for Uncomplicated Urinary …
However, the use of short course beta-lactam treatment in UTI is controversial. A RCT published after this analysis indicated that 3 days of beta-lactam (amoxicillin-clavulanate) therapy was …
In Vitro Models for the Study of Combination Antibiotic …
dime. Some authors [4-81 have studied two beta-lactam agents in combination and others [9,10] have used newer, more potent beta-lactam antibiotics alone. In one study [6] that compared …
Initial Antibiotic Selection and De-escalation in Sepsis
(a.k.a. “double coverage”) to accelerate clearance Initial use for patients in septic shock with a suspected gram-negative infection based on local epidemiology (increased local resistance) …
Adult Extended Infusion POLICY XX.XX.XX …
continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med 2015;192(11):1298-1305. 14. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of …
UCSF Medical Center Extended Infusion Zosyn Protocol_16
continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med 2015;192(11):1298-1305. 14. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of …
Penicillin Oral Desensitization Protocol Patient Eligibility and ...
antibiotic therapy MUST be initiated immediately after completion of desensitization. If subsequent beta-lactam therapy is needed in the future, the allergy should be re-evaluated, and …
Continuous Infusion of Beta-Lactam Antibiotics in Severe …
MAJOR ARTICLE Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial Joel M. Dulhunty, 1Jason A. Roberts, Joshua S. …
Kajian Literatur: Efektivitas Antibiotik Golongan Beta-Laktam …
effectiveness of beta-lactam antibiotics in the elderly with community pneumonia is determined by 3 criteria, including clinical efficacy, microbiological efficacy, and treatment duration. Overall, …
Ceftazidime-avibactam with or without Aztreonam vs …
beta-lactamase (NDM) and OXA-48 enzymes.6,7 Ceftazidime-avibactam (CAZ-AVI) is a novel beta lactam-beta lactamase inhibitor that has shown promise in combating infections caused …
Z E ‘SYNERGY’ AND IN-VITRO SUSCEPTIBILITY? - ResearchGate
We systematically determined the relationship between double beta-lactam therapy against 7 Escherichia coli (E. coli) strains of variable resistance in-vitro (4 clinical/3 purchased). This ...
Guidelines for Treatment of Urinary Tract Guidelines
May 11, 2021 · 4 • Empiric antibiotic choice should take into consideration recent previous culture results, prior antibiotic use, antibiotic allergies, local antibiotic susceptibilities, and severity of …
San Francisco VA Medical Center Antimicrobial Guidebook …
Apr 14, 2022 · 4 Phone/Pager Numbers ASP/ID Pharmacist Sunday - Wednesday Pager (415) 223 – 8046 or EXT 25269 ASP/ID Pharmacist Wednesday - Saturday Pager (415) 223 – 8046 …
Pfizer Pipeline
Feb 4, 2025 · CTB+AVP (PF-07612577) Beta lactam/Beta lactamase inhibitor Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis (FAST TRACK – U.S.) Phase 1 New …
Carbapenem Resistant Enterobacterales - Emory School of …
•ESBL – Extended spectrum beta-lactamase •Defined as enzymes produced by certain bacteria that are able to hydrolyze extended spectrum cephalosporin. •Effective against beta-lactam …
Brand Name: Zerbaxa
The beta-lactam ring of tazobactam is hydrolyzed to form the pharmacologically inactivetazobactam metabolite M1. (3) ... double-blind, phase 3 trial (ASPECT-cUTI). Lancet. …
TREATMENT PATHWAY FOR ADULT PATIENTS WITH …
NOTE: See Beta-lactam Allergy Evaluation and Empiric Therapy Guidance document for further allergy information. High-risk allergies are defined as: respiratory symptoms (chest tightness, …
Treatment Duration for Uncomplicated Community-Acquired …
In the intervention group, 70.1% qualified for and received 5 days of therapy. There were 13/162 protocol violations that were not included in the per protocol analysis. Of the cohort …
SHC Community Acquired Pneumonia: Antimicrobial Selection …
Duration of Therapy: Duration of therapy for inpatient CAP is 5 days with clinical improvement, resolution of hypoxia, and absence of complicating factors (e.g. meningitis, endocarditis, other …
Detailed regimens for the prolonged β-lactam infusion therapy
therapy and the initiation timing of post-loading prolonged infusion. However, there is no detailed note on the specific regimens of prolonged β-lactam infusion in the article [1], leaving a …
The double-tongue sign - ccjm.org
The double-tongue sign Nami Yoshimura, MD Department of General Medicine, ... and the patient was prescribed antibiotic therapy with intravenous ampicillin-sulbactam 1.5 g every 12 hours for …
Continuous Infusion of Beta-Lactam Antibiotics in Severe …
MAJOR ARTICLE Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial Joel M. Dulhunty, 1Jason A. Roberts, Joshua S. …
2020 Resident Orientation Pharmacy Department - University …
•Make therapy suggestions for modifications to streamline therapy, make dosages adjustments for better efficacy, stop unnecessary antibiotics ... •Automatic discontinuation of double beta …
Microbiology Misconceptions - University of California, Los …
therapy when the bacterial burden has decreased. Infectious Diseases consultation is highly recommended in such cases. The second agent should be an aminoglycoside in most cases. …
Duration of Antibiotic Treatment for Uncomplicated Urinary …
However, the use of short course beta-lactam treatment in UTI is controversial. A RCT published after this analysis indicated that 3 days of beta-lactam (amoxicillin-clavulanate) therapy was …
Macro Micro Misconceptions
therapy when the bacterial burden has decreased. Infectious Diseases consutlation is highly recommended in such cases. The second agent should be an aminoglycoside in most cases. …
Community Acquired Pneumonia in Adults - Antibiotic …
B. Drug-resistant S. pneumoniae (DRSP): Risk factors for infection with b-lactam–resistant S. pneumoniae include age > 65 years, beta-lactam therapy within the previous 3 months, …
Potential risks of treating bacterial infections with a …
glycoside with a b-lactam.12,32 36 Although b-lactam/aminoglycoside combinations are extensively used, there is an important parameter of this combination therapy that is often left …
CASE REPORT One stage extraction and reimplantation of …
and spondiloscitis due to E. faecalis treated with double beta-lactam combination: ampicillin plus ceftobiprole Maria Lucia Narducci1, Davide Pecori2, ... nation therapy with ampicillin, based on …
第40回セミナー 講演および症例提示に関するQ&A
クロキサシリン・アンピシリンの合剤はdouble beta-lactam となりクロキサシリン単剤（もしくはセフ ァゾリン）より治療効果が減弱する可能性はないでしょうか？ 回答：治療効果が減 …
